Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPAgliflozin Once Daily for Cardio-Renal Outcomes in Chronic Kidney Disease (CKD)
2017-002971-24Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Empagliflozin arm with Placebo arm (2 arms). Primary endpoint: Primary composite renal and cardiovascular outcome. Started May 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2017-002971-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002971-24.